期刊
CANCER LETTERS
卷 476, 期 -, 页码 1-12出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.02.002
关键词
Glioma; Immunotherapy; Checkpoint; Oncolytic virus; Vaccine
类别
资金
- National Natural Science Foundation of China [81472693, 81873635]
- Natural Science Foundation of Hunan Province [2019JJ50963]
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells. Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved limited improvements in the prognosis of glioma patients. Immunotherapy, a revolution in cancer treatment, has become a promising strategy with the ability to penetrate the blood-brain barrier since the pioneering discovery of lymphatics in the central nervous system. Here we detail the current management of gliomas and previous studies assessing different immunotherapies in gliomas, despite the fact that the associated clinical trials have not been completed yet. Moreover, several drugs that have undergone clinical trials are listed as novel strategies for future application; however, these clinical trials have indicated limited efficacy in glioma. Therefore, additional studies are warranted to evaluate novel therapeutic approaches in glioma treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据